From GlobeNewswire: 2025-03-13 07:00:00

Apyx Medical Corporation reported total revenue of $14.2 million in Q4 2024, driven by U.S. capital equipment and single-use handpiece sales growth. The company’s net loss attributable to stockholders decreased by 52% to $4.6 million compared to the same period last year. They submitted a 510(k) premarket notification to the U.S. FDA for the AYON™ Body Contouring System ahead of schedule.

In Q4 2024, the company’s Advanced Energy revenue exceeded expectations at $12.1 million, driven by strong generator unit sales and U.S. single-use handpiece sales. They also closed a $7.0 million registered direct offering and implemented a cost-saving restructuring program. Apyx Medical aims to launch the AYON system in the back half of 2025, pending FDA clearance.

For the full year 2024, Apyx Medical reported a total revenue of $48.1 million, an 8% decrease from the previous year. The company’s gross profit margin was 61.0%, and they reduced operating expenses to $48.2 million. Apyx Medical refined its financial guidance for 2025, targeting total revenue in the range of $47.6 million to $49.0 million and operating expenses below $40.0 million.

Adjusted EBITDA, a non-GAAP financial measure, improved to a loss of $2.2 million in Q4 2024 compared to $4.7 million in the same period last year. The company’s net loss for the quarter was $4.6 million, down from $9.6 million in Q4 2023. Apyx Medical’s total equity as of December 31, 2024, was $14.2 million. Management will host a conference call today at 8:30 a.m. ET to discuss these results.



Read more at GlobeNewswire:: Apyx Medical Corporation Reports Fourth Quarter and Full